Seaweed Secondary Metabolites with Beneficial Health Effects : An Overview of Successes in In Vivo Studies and Clinical Trials
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.3/5787 |
Resumo: | Macroalgae are increasingly viewed as a source of secondary metabolites with great potential for the development of new drugs. In this development, in vitro studies are only the first step in a long process, while in vivo studies and clinical trials are the most revealing stages of the true potential and limitations that a given metabolite may have as a new drug. This literature review aims to give a critical overview of the secondary metabolites that reveal the most interesting results in these two steps. Phlorotannins show great pharmaceutical potential in in vivo models and, among the several examples, the anti-dyslipidemia activity of dieckol must be highlighted because it was more effective than lovastatin in an in vivo model. The IRLIIVLMPILMA tridecapeptide that exhibits an in vivo level of activity similar to the hypotensive clinical drug captopril should still be stressed, as well as griffithsin which showed such stunning results over a variety of animal models and which will probably move onto clinical trials soon. Regarding clinical trials, studies with pure algal metabolites are scarce, limited to those carried out with kahalalide F and fucoxanthin. The majority of clinical trials currently aim to ascertain the effect of algae consumption, as extracts or fractions, on obesity and diabetes. |
id |
RCAP_ce882a2c233708d879a18f38f2ad018a |
---|---|
oai_identifier_str |
oai:repositorio.uac.pt:10400.3/5787 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Seaweed Secondary Metabolites with Beneficial Health Effects : An Overview of Successes in In Vivo Studies and Clinical TrialsSeaweedsSecondary Metabolitesin vivo StudiesClinical TrialsHealth EffectsDieckolEckolFucoxanthinKahalalide FMacroalgae are increasingly viewed as a source of secondary metabolites with great potential for the development of new drugs. In this development, in vitro studies are only the first step in a long process, while in vivo studies and clinical trials are the most revealing stages of the true potential and limitations that a given metabolite may have as a new drug. This literature review aims to give a critical overview of the secondary metabolites that reveal the most interesting results in these two steps. Phlorotannins show great pharmaceutical potential in in vivo models and, among the several examples, the anti-dyslipidemia activity of dieckol must be highlighted because it was more effective than lovastatin in an in vivo model. The IRLIIVLMPILMA tridecapeptide that exhibits an in vivo level of activity similar to the hypotensive clinical drug captopril should still be stressed, as well as griffithsin which showed such stunning results over a variety of animal models and which will probably move onto clinical trials soon. Regarding clinical trials, studies with pure algal metabolites are scarce, limited to those carried out with kahalalide F and fucoxanthin. The majority of clinical trials currently aim to ascertain the effect of algae consumption, as extracts or fractions, on obesity and diabetes.This research was funded by project MACBIOBLUE (MAC/1.1b/086), program Interreg MAC 2014–2020 co-financed by DRCT (Azores Regional Government), supporting G.P. Rosa’s grant, as well as by FCT—Fundação para a Ciência e a Tecnologia, the European Union, QREN, FEDER, and COMPETE, through funding the cE3c center (FCT UID/BIA/00329/2013, 2015–2018 and UID/BIA/00329/2019) and the QOPNA research unit (FCT UID/QUI/00062/2019)MDPIRepositório da Universidade dos AçoresRosa, Gonçalo P.Tavares, Wilson R.Sousa, Pedro M. C.Pagès, Aida K.Seca, Ana M. L.Pinto, Diana C. G. A.2021-03-12T17:51:55Z2019-12-202019-12-20T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.3/5787engRosa, G.P., Tavares, W.R., Sousa, P.M.C., Pagès, A.K., Seca, A.M.L. & Pinto, D.C.G.A. (2020). Seaweeds secondary metabolites with beneficial health effects: an overview of successes in in vivo studies and clinical trials. "Marine Drugs", 18(1), 8. DOI:10.3390/md180100081660-339710.3390/md18010008000513184600001info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-12-20T14:34:08Zoai:repositorio.uac.pt:10400.3/5787Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:27:56.129890Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Seaweed Secondary Metabolites with Beneficial Health Effects : An Overview of Successes in In Vivo Studies and Clinical Trials |
title |
Seaweed Secondary Metabolites with Beneficial Health Effects : An Overview of Successes in In Vivo Studies and Clinical Trials |
spellingShingle |
Seaweed Secondary Metabolites with Beneficial Health Effects : An Overview of Successes in In Vivo Studies and Clinical Trials Rosa, Gonçalo P. Seaweeds Secondary Metabolites in vivo Studies Clinical Trials Health Effects Dieckol Eckol Fucoxanthin Kahalalide F |
title_short |
Seaweed Secondary Metabolites with Beneficial Health Effects : An Overview of Successes in In Vivo Studies and Clinical Trials |
title_full |
Seaweed Secondary Metabolites with Beneficial Health Effects : An Overview of Successes in In Vivo Studies and Clinical Trials |
title_fullStr |
Seaweed Secondary Metabolites with Beneficial Health Effects : An Overview of Successes in In Vivo Studies and Clinical Trials |
title_full_unstemmed |
Seaweed Secondary Metabolites with Beneficial Health Effects : An Overview of Successes in In Vivo Studies and Clinical Trials |
title_sort |
Seaweed Secondary Metabolites with Beneficial Health Effects : An Overview of Successes in In Vivo Studies and Clinical Trials |
author |
Rosa, Gonçalo P. |
author_facet |
Rosa, Gonçalo P. Tavares, Wilson R. Sousa, Pedro M. C. Pagès, Aida K. Seca, Ana M. L. Pinto, Diana C. G. A. |
author_role |
author |
author2 |
Tavares, Wilson R. Sousa, Pedro M. C. Pagès, Aida K. Seca, Ana M. L. Pinto, Diana C. G. A. |
author2_role |
author author author author author |
dc.contributor.none.fl_str_mv |
Repositório da Universidade dos Açores |
dc.contributor.author.fl_str_mv |
Rosa, Gonçalo P. Tavares, Wilson R. Sousa, Pedro M. C. Pagès, Aida K. Seca, Ana M. L. Pinto, Diana C. G. A. |
dc.subject.por.fl_str_mv |
Seaweeds Secondary Metabolites in vivo Studies Clinical Trials Health Effects Dieckol Eckol Fucoxanthin Kahalalide F |
topic |
Seaweeds Secondary Metabolites in vivo Studies Clinical Trials Health Effects Dieckol Eckol Fucoxanthin Kahalalide F |
description |
Macroalgae are increasingly viewed as a source of secondary metabolites with great potential for the development of new drugs. In this development, in vitro studies are only the first step in a long process, while in vivo studies and clinical trials are the most revealing stages of the true potential and limitations that a given metabolite may have as a new drug. This literature review aims to give a critical overview of the secondary metabolites that reveal the most interesting results in these two steps. Phlorotannins show great pharmaceutical potential in in vivo models and, among the several examples, the anti-dyslipidemia activity of dieckol must be highlighted because it was more effective than lovastatin in an in vivo model. The IRLIIVLMPILMA tridecapeptide that exhibits an in vivo level of activity similar to the hypotensive clinical drug captopril should still be stressed, as well as griffithsin which showed such stunning results over a variety of animal models and which will probably move onto clinical trials soon. Regarding clinical trials, studies with pure algal metabolites are scarce, limited to those carried out with kahalalide F and fucoxanthin. The majority of clinical trials currently aim to ascertain the effect of algae consumption, as extracts or fractions, on obesity and diabetes. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-12-20 2019-12-20T00:00:00Z 2021-03-12T17:51:55Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.3/5787 |
url |
http://hdl.handle.net/10400.3/5787 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Rosa, G.P., Tavares, W.R., Sousa, P.M.C., Pagès, A.K., Seca, A.M.L. & Pinto, D.C.G.A. (2020). Seaweeds secondary metabolites with beneficial health effects: an overview of successes in in vivo studies and clinical trials. "Marine Drugs", 18(1), 8. DOI:10.3390/md18010008 1660-3397 10.3390/md18010008 000513184600001 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
MDPI |
publisher.none.fl_str_mv |
MDPI |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130736578527232 |